Leqvio vs Amlodipine: Cost and Access Head-to-Head

Why These Two Drugs Get Compared

Leqvio and amlodipine sit in entirely different pharmacologic categories, yet they appear side by side in cardiometabolic formulary discussions because many patients with atherosclerotic cardiovascular disease (ASCVD) take both a lipid-lowering agent and an antihypertensive. The comparison is really about budget allocation: can a health system justify adding a $13,000-per-year injectable when patients already pay almost nothing for amlodipine?

The answer depends on what each drug actually does. Amlodipine blocks L-type calcium channels in vascular smooth muscle, reducing peripheral resistance and lowering blood pressure 1. It does not meaningfully reduce LDL cholesterol. Leqvio (inclisiran) is a small interfering RNA that silences hepatic PCSK9 production, cutting LDL-C by approximately 50% on top of maximally tolerated statin therapy 2. These mechanisms do not overlap. A patient with both uncontrolled hypertension and residual LDL-C elevation may need both drugs, not one or the other. The cost question is therefore not "which one do I pick?" but "is the added expense of Leqvio justified given what amlodipine already covers?"

Mechanism and Clinical Targets

Inclisiran binds to PCSK9 messenger RNA inside hepatocytes, triggering its degradation through the RNA-induced silencing complex (RISC). The result is sustained PCSK9 protein suppression and upregulation of LDL receptors on the liver surface. ORION-10 (N=1,561) and ORION-11 (N=1,617) demonstrated that inclisiran 284 mg, given subcutaneously at day 1, day 90, and every 6 months thereafter, reduced LDL-C by 52.3% and 49.9% respectively versus placebo at day 510 2.

Amlodipine works downstream of lipid metabolism entirely. In the ASCOT-BPLA trial (N=19,257), the amlodipine-based regimen reduced total cardiovascular events by 16% compared with atenolol-based treatment over a median 5.5 years 1. That benefit came from blood pressure control, not lipid changes. The lipid arm of ASCOT (ASCOT-LLA) tested atorvastatin 10 mg against placebo and found a 36% relative risk reduction in primary coronary events 3, confirming that lipid lowering on top of an amlodipine-based BP regimen adds independent benefit.

No head-to-head trial has ever tested inclisiran directly against amlodipine. Such a trial would make little clinical sense. They target different risk factors.

Cost Breakdown: Wholesale, Net, and Out-of-Pocket

The price gap between these two drugs is among the widest in cardiology. Leqvio carries a wholesale acquisition cost (WAC) of approximately $6,500 per injection, translating to roughly $13,000 per year for the maintenance phase (two doses annually after the loading period) 4. Generic amlodipine besylate 5 mg or 10 mg costs between $4 and $15 for a 30-day supply at most retail pharmacies, placing the annual spend below $50 in many cases.

Net price after rebates tells a different story for Leqvio, though it remains expensive. Novartis has negotiated outcomes-based contracts with several large payers and PBMs. The company also runs a patient support program (Leqvio Complete) offering $0 copay cards for commercially insured patients meeting eligibility criteria. For Medicare Part B beneficiaries, Leqvio is covered as a physician-administered drug under the medical benefit, meaning the 20% coinsurance on roughly $6,500 could still leave patients owing over $1,300 per injection before supplemental coverage kicks in.

Amlodipine, by contrast, sits on Tier 1 of virtually every commercial and Medicare Part D formulary. Most patients pay a flat copay of $0 to $10 per month. No prior authorization is required. No specialty pharmacy routing is needed. The drug is available at every retail and mail-order pharmacy in the country.

Insurance Access and Prior Authorization

Getting amlodipine covered requires nothing beyond a prescription. Getting Leqvio covered requires documentation that the patient has established ASCVD or heterozygous familial hypercholesterolemia (HeFH), is on maximally tolerated statin therapy, and still has an LDL-C above goal (typically >70 mg/dL for very high-risk patients per 2018 AHA/ACC guidelines) 5.

Prior authorization for Leqvio commonly requires three elements: a documented statin trial (or documented statin intolerance), a recent LDL-C lab result, and a diagnosis code for ASCVD or HeFH. Turnaround times vary from 48 hours to 3 weeks depending on the payer. Some plans also impose step therapy, requiring a trial of ezetimibe or a PCSK9 monoclonal antibody (evolocumab or alirocumab) before approving inclisiran.

Medicare Part B coverage for Leqvio is handled differently than Part D oral drugs. Because inclisiran is administered by a healthcare professional, it falls under the medical benefit. The 2023 Inflation Reduction Act provisions that cap Part D out-of-pocket spending at $2,000 annually do not apply to Part B drugs. Patients relying on Medicare may face meaningful coinsurance obligations unless they carry Medigap or employer-sponsored supplemental insurance.

Commercial plans with specialty pharmacy carve-outs may route Leqvio through a buy-and-bill arrangement at the physician's office or through a specialty pharmacy that ships directly to the administering clinic. Dr. Seth Baum, president of the American Society for Preventive Cardiology, has noted: "The biggest barrier to inclisiran uptake is not clinical skepticism. It is the administrative friction of getting the drug approved and delivered to the point of care." That friction adds hidden costs in staff time, phone calls, and appointment delays.

Efficacy in Context: What Each Drug Actually Delivers

Comparing efficacy numbers across these two drugs requires acknowledging they measure success differently. Leqvio's primary endpoint in ORION-10 and ORION-11 was percent change in LDL-C from baseline. At day 510, pooled data showed a time-averaged LDL-C reduction of 50.5% versus placebo 2. The absolute LDL-C reduction averaged approximately 55 to 60 mg/dL depending on baseline values.

Amlodipine's efficacy is measured in millimeters of mercury. At 10 mg daily, amlodipine typically reduces systolic blood pressure by 12 to 18 mmHg and diastolic by 6 to 10 mmHg 6. In ASCOT-BPLA, the amlodipine-perindopril arm achieved a mean BP of 136/77 mmHg versus 138/79 mmHg in the atenolol-bendroflumethiazide arm, a modest numerical difference that translated into significant event reduction over 5.5 years 1.

The critical missing piece for Leqvio is a completed cardiovascular outcomes trial. ORION-4 (N=15,000, expected completion 2026) will determine whether inclisiran's LDL-C reduction translates into reduced major adverse cardiovascular events (MACE) 7. Until those data arrive, clinicians rely on the established log-linear relationship between LDL-C lowering and CV event reduction (roughly 22% relative risk reduction per 1 mmol/L LDL-C decrease, per CTT Collaboration meta-analysis) 8.

Amlodipine, in contrast, has decades of outcomes data across multiple large trials including ASCOT, ALLHAT, and VALUE. That evidence base is one reason payers rarely question its value.

Dosing Convenience and Adherence

Leqvio's twice-yearly dosing schedule is its most distinctive practical advantage. After the initial dose and a 3-month booster, patients return only every 6 months for a subcutaneous injection administered by a healthcare professional. This eliminates daily pill burden for the lipid-lowering component. Real-world adherence to daily statins falls to roughly 50% by 12 months 9. Twice-yearly dosing could sidestep that adherence cliff entirely.

Amlodipine adherence is generally better than statin adherence but still imperfect. A 2019 meta-analysis found 12-month persistence with antihypertensives ranges from 30% to 70% depending on drug class, with amlodipine performing near the upper end of that range due to its once-daily dosing and mild side-effect profile 10.

The trade-off: Leqvio requires an in-person clinical visit for every dose. Patients in rural areas or those with mobility limitations may find biannual clinic visits more burdensome than picking up a monthly prescription. The American College of Cardiology's 2022 Expert Consensus Decision Pathway notes that "patient access to an administering site should factor into prescribing decisions for inclisiran" 11.

Safety and Side-Effect Profiles

Both drugs are well-tolerated. That is where the similarities end.

Amlodipine's most common adverse effect is peripheral edema, occurring in 5% to 15% of patients at 10 mg daily 6. Other reported effects include dizziness, flushing, and fatigue. Serious adverse events are rare. Amlodipine does not require liver function monitoring. It is safe in patients with renal impairment and mild hepatic dysfunction, though dose reduction is recommended in severe liver disease.

Inclisiran's main adverse event in ORION-10 and ORION-11 was injection-site reaction, occurring in 8.2% of inclisiran patients versus 1.8% on placebo 2. These reactions were generally mild (erythema, pain, rash) and did not lead to treatment discontinuation in any patient during the trial. Serious hepatic events were not increased versus placebo. No myalgia signal has been observed, distinguishing inclisiran from statins in a population that often cites muscle symptoms as a barrier to lipid therapy.

Long-term safety data beyond 4 years remain limited for inclisiran. The ORION long-term extension studies (ORION-3, ORION-8) are ongoing. Amlodipine has a 35-plus-year track record in clinical practice and post-marketing surveillance.

Who Should Consider Each Drug (and Who Might Need Both)

The patient who benefits most from Leqvio is someone with established ASCVD or HeFH whose LDL-C remains above goal despite maximally tolerated statin and ezetimibe therapy. According to the 2018 AHA/ACC cholesterol guideline, the LDL-C threshold for adding a non-statin agent in very high-risk ASCVD patients is 70 mg/dL 5.

The patient who benefits most from amlodipine is someone with hypertension (stage 1 or 2), chronic stable angina, or vasospastic angina requiring long-acting calcium channel blockade.

Many patients fit both profiles. A 62-year-old with a prior MI, LDL-C of 85 mg/dL on rosuvastatin 40 mg plus ezetimibe, and blood pressure of 148/92 mmHg may need both Leqvio and amlodipine. In that scenario the drugs are complementary, not competitive. The real question for the patient and the payer is whether adding a $13,000-per-year injectable is cost-effective when generic amlodipine, a generic statin, and generic ezetimibe together cost under $300 annually.

Cost-effectiveness analyses published before ORION-4 results generally place inclisiran at $50,000 to $150,000 per quality-adjusted life year (QALY) depending on the model assumptions, baseline LDL-C, and assumed CV event reduction 12. If ORION-4 confirms a MACE benefit proportional to the observed LDL-C reduction, inclisiran's ICER will likely fall below the commonly cited $100,000/QALY willingness-to-pay threshold. If the trial shows a smaller-than-expected benefit, payers may restrict access further.

Generic Availability and Future Pricing

Amlodipine has been available as a generic since 2007 (U.S.) after Pfizer's Norvasc patent expired. Biosimilar or generic competition for Leqvio is not expected before the 2030s at the earliest. Novartis holds composition-of-matter and formulation patents on inclisiran sodium, and the siRNA manufacturing process is more complex than small-molecule synthesis, creating higher barriers to generic entry.

The Inflation Reduction Act's Medicare drug price negotiation program could eventually include Leqvio, but only Part D drugs are eligible in the initial rounds. Because Leqvio is a Part B physician-administered drug, it falls outside the current negotiation framework. Legislative changes could alter this, but no concrete timeline exists as of mid-2026.

For now, the cost asymmetry between these drugs is likely to persist for at least another 5 to 7 years.

Practical Steps for Patients Weighing Cost

Patients considering Leqvio should ask their cardiologist or lipid specialist three questions before starting: (1) Does my insurance cover Leqvio, and what is my expected out-of-pocket per dose? (2) Am I eligible for the Novartis $0 copay program or patient assistance? (3) Is there an administering site within reasonable travel distance? For amlodipine, the primary question is simpler: is my blood pressure adequately controlled, and am I tolerating the current dose without significant edema?

The ACC's 2022 consensus pathway recommends a shared decision-making conversation that includes out-of-pocket cost estimates before prescribing any PCSK9-targeted therapy 11. Patients who qualify for manufacturer assistance programs may pay $0 for Leqvio; patients without such coverage could face annual costs exceeding $2,600 in coinsurance alone under Medicare Part B.

Amlodipine 10 mg daily, filled at a cost-plus pharmacy, runs approximately $3.50 per month.